Latest KFF Health News Stories
Survey: Americans Want Weight Loss Drugs Despite High Cost
A new poll reveals enthusiasm for a pricey new generation of weight loss drugs, but interest drops if users potentially have to deal with weekly injections, lack of insurance coverage, or a need to continue the medications indefinitely to avoid regaining weight.
The Real Costs of the New Alzheimer’s Drug, Most of Which Will Fall to Taxpayers
The annual cost of lecanemab treatment quadruples if the expense of brain scans to monitor for bleeds and other associated care is factored in. The full financial toll likely puts it beyond reach for low-income seniors at risk of Alzheimer’s, experts say.
New Weight Loss Drugs Carry High Price Tags and Lots of Questions for Seniors
Although nearly 40% of Americans 60 and older are obese, Medicare doesn’t cover weight loss medications. Meanwhile, studies haven’t thoroughly examined new drugs’ impact on older adults.
KFF Health News' 'What the Health?': The Long Road to Reining In Short-Term Plans
President Biden made good on a campaign promise this week with a proposal that would limit short-term health insurance plans that boast low premiums but also few benefits. Meanwhile, the Supreme Court’s decision to outlaw affirmative action programs could set back efforts to diversify the nation’s medical workforce. Alice Miranda Ollstein of Politico, Amy Goldstein of the Washington Post, and Rachel Cohrs of Stat News join KFF Health News’ chief Washington correspondent Julie Rovner to discuss these issues and more. Also this week, Rovner interviews KFF Health News’ Bram Sable-Smith, who reported the latest KFF Health News-NPR “Bill of the Month” about how a hospital couldn’t track down a patient, but a debt collector could.
Pharmacy benefit managers, or PBMs, are companies that negotiate the prices of prescription drugs. Hear about their role in raising drug prices and the ongoing efforts to regulate this complex industry.
What You Need to Know About the Drug Price Fight in Those TV Ads
At least nine bills introduced in Congress take aim at pharmacy benefit managers, the powerful middlemen that channel prescription drugs to patients.
Patients Squeezed in Fight Over Who Gets to Bill for Pricey Infusion Drugs
To drive down costs, insurers are bypassing hospital system pharmacies and delivering high-priced infusion drugs, including some used in chemotherapy, via third-party pharmacies. Smarting from losing out on billing for those drugs, hospitals and clinics are trying to convince states to limit this practice, known as “white bagging.”
KFF Health News' 'What the Health?': Slow Your Disenroll
More than a million Americans have lost Medicaid coverage since pandemic protections ended. The Biden administration is asking states to slow disenrollment, but that does not mean states must listen. Meanwhile, a Supreme Court decision gives Medicaid beneficiaries the right to sue over their care, and a new deal preserves coverage of preventive services nationwide as a Texas court case continues. Rachel Cohrs of Stat, Alice Miranda Ollstein of Politico, and Sandhya Raman of CQ Roll Call join KFF Health News’ Mary Agnes Carey to discuss these issues and more. Also this week, KFF Health News’ Julie Rovner interviews Dan Mendelson, CEO of Morgan Health, a new unit of JPMorgan Chase, about employers’ role in insurance coverage.
KFF Health News' 'What the Health?': Debt Deal Leaves Health Programs (Mostly) Intact
The bipartisan deal to extend the U.S. government’s borrowing authority includes future cuts to federal health agencies, but they are smaller than many expected and do not touch Medicare and Medicaid. Meanwhile, Merck & Co. becomes the first drugmaker to sue Medicare officials over the federal health insurance program’s new authority to negotiate drug prices. Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico, Lauren Weber of The Washington Post, and Jessie Hellmann of CQ Roll Call join KFF Health News’ chief Washington correspondent, Julie Rovner, to discuss these issues and more. Also this week, Rovner interviews KFF Health News senior correspondent Sarah Jane Tribble, who reported the latest KFF Health News-NPR “Bill of the Month” feature, about the perils of visiting the U.S. with European health insurance.
Many People Living in the ‘Diabetes Belt’ Are Plagued With Medical Debt
The “Diabetes Belt,” as defined by the Centers for Disease Control and Prevention, comprises 644 mostly Southern counties where diabetes rates are high. Of those counties, KFF Health News and NPR found, more than half also have high levels of medical debt.
KFF Health News' 'What the Health?': When an Anti-Vaccine Activist Runs for President
Robert F. Kennedy Jr.’s official entry into the presidential race poses a thorny challenge for journalists: how to cover a candidate who’s opposed to vaccines without amplifying misinformation. And South Carolina becomes the latest state in the South to ban abortion after roughly six weeks of pregnancy. Alice Miranda Ollstein of Politico, Rachel Cohrs of Stat, and Sarah Karlin-Smith of the Pink Sheet join KFF Health News chief Washington correspondent Julie Rovner to discuss these issues and more. Also this week, Rovner interviews KFF Health News senior correspondent Aneri Pattani about her project to track the billions of dollars coming from opioid makers to settle lawsuits.
This Panel Will Decide Whose Medicine to Make Affordable. Its Choice Will Be Tricky.
Colorado’s new Prescription Drug Affordability Board could cap what health plans and consumers pay for certain medications starting next year. The process will pit patient groups against one another.
A More Aggressive FTC Is Starting to Target Drug Mergers and Industry Middlemen
Industry analysts are skeptical that Federal Trade Commission Chair Lina Khan can win her first fight against a drug industry merger. It will be reviewed by a judge appointed by then-President Donald Trump.
La Comisión Federal de Comercio está actuando contra las empresas farmacéuticas y los intermediarios del sector, como parte de la campaña de la administración Biden para reducir los precios de los medicamentos en las farmacias.
Are US Prescription Drug Prices 10 Times Those of Other Nations? Only Sometimes
Sen. Bernie Sanders’ broad statement that some U.S. drug prices are 10 times those of other nations doesn’t paint the full picture. Studies we examined generally found that U.S. prices were two to four times those in other countries, not 10.
PBMs, the Brokers Who Control Drug Prices, Finally Get Washington’s Attention
Drugmakers, pharmacies, and physicians blame pharmacy benefit managers for high drug prices. Congress is finally on board, too, but will it matter?
KFF Health News' 'What the Health?': Dancing Under the Debt Ceiling
House Republicans passed their plan to raise the nation’s debt ceiling, along with major cuts to health (and other domestic) programs. Unlikely to become law, it calls for new work requirements for adults on Medicaid. Meanwhile, state efforts targeting trans people bear a striking resemblance to the fight against abortion rights. Jessie Hellmann of CQ Roll Call, Shefali Luthra of The 19th, and Sarah Karlin-Smith of the Pink Sheet join KFF Health News chief Washington correspondent Julie Rovner to discuss these issues and more. Also this week, Rovner interviews Renuka Rayasam, who reported the latest KFF Health News-NPR “Bill of the Month” feature, about a specialist’s demand to be paid as much as $15,000 before treating a woman’s serious pregnancy complication.
KFF Health News' 'What the Health?': Will They or Won’t They (Block the Abortion Pill)?
The Supreme Court is considering the future of the abortion pill mifepristone, after GenBioPro sued the FDA over limitations that effectively block generic production of the drug, a major part of the market. Congress is considering proposals that would impose Medicaid work requirements, crack down on pharmacy benefit managers, and more. And President Joe Biden moved to expand health coverage to young immigrants known as “Dreamers.” Rachel Cohrs of Stat, Sandhya Raman of CQ Roll Call, and Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico join KFF Health News’ Mary Agnes Carey to discuss these issues and more.
Redes sociales alimentan obsesión por las drogas para bajar de peso, sin hablar de riesgos
La competencia para hacerse con un mercado que podría valer $100.000 millones al año, solo para los fabricantes de medicamentos, ha desencadenado una ola de publicidad que preocupa a las autoridades sanitarias y médicos de todo el mundo.
Social Media Is Fueling Enthusiasm for New Weight Loss Drugs. Are Regulators Watching?
Online platforms are overflowing with testimonials for GLP-1s. The drugs show promise for inducing weight loss, but many aren’t FDA-approved for that use.
